[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::43475268.png) @bio_clouseau M

M posts on X about $apls, $isee, $srpt, mentions the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::43475268/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43475268/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +27%
- X Year XXXXXXXXX +48%

### Mentions: X [#](/creator/twitter::43475268/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43475268/c:line/m:posts_active.svg)

- X Week XX +130%
- X Month XX -XX%
- X Months XXX +8.30%
- X Year XXX +221%

### Followers: XXXXXX [#](/creator/twitter::43475268/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43475268/c:line/m:followers.svg)

- X Week XXXXXX +0.22%
- X Month XXXXXX +0.53%
- X Months XXXXXX +2.10%
- X Year XXXXXX +5%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::43475268/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43475268/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::43475268/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX% [finance](/list/finance)  XXXX% [currencies](/list/currencies)  XXXX%

**Social topic influence**
[$apls](/topic/$apls) 2.38%, [$isee](/topic/$isee) 2.38%, [$srpt](/topic/$srpt) 1.19%, [mentions](/topic/mentions) 1.19%, [$rare](/topic/$rare) 1.19%, [$mdgl](/topic/$mdgl) 1.19%, [$alpmy](/topic/$alpmy) 1.19%, [has been](/topic/has-been) 1.19%, [aes](/topic/aes) 1.19%, [$cogt](/topic/$cogt) XXXX%

**Top accounts mentioned or mentioned by**
[@jq1234t](/creator/undefined) [@jacobplieth](/creator/undefined) [@bertrandbio](/creator/undefined) [@sanctuarybio](/creator/undefined) [@sirtsix](/creator/undefined) [@nolastevedore](/creator/undefined) [@byamybrown](/creator/undefined) [@bymadeleinea](/creator/undefined) [@bradloncar](/creator/undefined) [@syinvesting](/creator/undefined) [@gcbioinv](/creator/undefined) [@evaluatevantage](/creator/undefined) [@applehelix](/creator/undefined) [@wallstarb](/creator/undefined) [@sanctuary_bio](/creator/undefined) [@chiragontwtr](/creator/undefined) [@pilldipp](/creator/undefined) [@dogehippie](/creator/undefined) [@avidresearch](/creator/undefined) [@ndrewcolburn](/creator/undefined)

**Top assets mentioned**
[Apellis Pharmaceuticals, Inc. Common Stock (APLS)](/topic/$apls) [IVERIC bio, Inc. Common Stock (ISEE)](/topic/$isee) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [SuperRare (RARE)](/topic/$rare) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Mirati Therapeutics, Inc. Common Stock (MRTX)](/topic/$mrtx) [Amgen, Inc. (AMGN)](/topic/$amgn) [AstraZeneca PLC (AZN)](/topic/$azn) [Blueprint Medicines Corporation (BPMC)](/topic/$bpmc)
### Top Social Posts [#](/creator/twitter::43475268/posts)
---
Top posts by engagements in the last XX hours

"$SRPT gets a platform tech designation on 6/4 for its AAVrh74 viral vector for LGMD 2E/R4 which seems to indicate the viral vector is "well understood" and "utilized by more than one drug without an adverse effect on quality manufacturing or safety". A little more than a month later FDA asks to voluntarily stop all shipments and issues a statement saying Sarepta "refused" the request and also pulls the platform designation just handed a month earlier. A lot of fingers being pointed at SRPT (rightfully)for being far from transparant but the FDA is not without fault either with its new found"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1946508655873995232) 2025-07-19 09:53:22 UTC 19.6K followers, 30.2K engagements


"Not sure of the details of the $RARE CRL but the post by the CEO refutes some of the rhetoric coming from the fda with respect to flexibility for rare diseases. Though the company PR mentions "months" to respond so in fairness to the FA its unclear that with a little more than a month to go what could have been done to avoid a CRL"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1944850235974414402) 2025-07-14 20:03:24 UTC 19.6K followers, 2502 engagements


"$MDGL 1st treatment against MASH in EU . Conditional approval dependent on 2nd trial"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1936005209341542823) 2025-06-20 10:16:25 UTC 19.6K followers, 7526 engagements


"If there is a buyer waiting for $APLS not apparent from $ISEE $ALPMY merger background. Number of interested parties though seem to be mainly for partnerships"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1660977648980443136) 2023-05-23 11:55:05 UTC 19.6K followers, 17.1K engagements


"Quite remarkable that most are equating some misleading mixed with bombastic statements to be good communication from the FDA. A sign of the times where simply "flooding the zone" works"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1944730944591556608) 2025-07-14 12:09:23 UTC 19.6K followers, 11.1K engagements


"Competitor bashing is quite frequent. Just a few years ago it was $ISEE and $APLS. Even between small and big like $MRTX and $AMGN and $CLVS $AZN (which didnt end well for the former). $BPMC has been involved in quite a few with $LOXO then $DCPH and now $COGT. I think they both have valid arguments. Ayvakit went from XXX /300 QD for AdvSM and GIST to 25mg to avoid the intracranial AE's. Remains to be seen how Bezu LT safety holds up though efficacy looks much better. Ava's 1st to market should help and even if Bezu struggles in ISM there is the GIST opportunity so not much to be bearish at a"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1936003314061074602) 2025-06-20 10:08:53 UTC 19.6K followers, 8200 engagements